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Background: Double-blind, placebo-controlled (DBPC) trials are the gold standard for demonstrating clinical
efficacy and tolerability. The placebo effect, although an important feature in placebo-controlled studies, has never
been systematically investigated in allergen-specific immunotherapy (SIT) studies. This study was performed to
examine the placebo response in SIT trials that employed a baseline observational period and two treatment years
using a symptom-medication-score (SMS) as the primary endpoint.
Methods: The placebo effect was evaluated in six DBPC SIT studies (five studies using subcutaneous SIT (SCIT) and
one sublingual (SLIT)), two grass, two birch and two house dust mite (HDM) SIT, including a total of 472 adult
patients treated with a placebo. The results were reported as changes from baseline of the SMS area under the
curve after two years of perennial placebo therapy during the respective evaluation periods. Pollen counts and IgG4
levels were additionally analysed.
Results: Subcutaneously treated placebo patients displayed a marked decrease in the SMS. The mean placebo
effect in the SCIT trials with comparable allergen exposure was up to 41% in the second treatment year and, in
contrast, reached only 1% in the SLIT trial. Allergen exposure had an inverse influence on the placebo effect. No
changes from baseline in allergen specific IgG4 antibodies were observed in the placebo-treated patients.
Conclusions: SIT studies display a significant placebo effect, mainly observed in subcutaneous immunotherapy,
with high variability depending on the route of application and allergen exposure. Our findings indicate the
differential role of the placebo effect in SIT efficacy depending on the route of administration and pollen exposure.
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Double-blind, randomised controlled trials provide the
highest level of evidence in clinical studies [1]. The major
purpose of control groups is to discriminate between ex-
perimental group outcomes caused by the active treatment
and those that are related to other factors, such as natural
progression of the disease, observer or patient expecta-
tions or other treatments [2]. Clinical studies can use dif-
ferent types of controls [2], but despite some ethical issues
[3], the use of placebos is considered the gold standard to
demonstrate clinical efficacy and tolerability for many me-
dicinal products [4].
The placebo design is said to control for all of the po-
tential influences on the course of a disease (other than* Correspondence: annemie.narkus@allergopharma.com
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stated.those arising from the pharmacologically active treat-
ment). These features include spontaneous improvement
(i.e., the natural history of the disease and regression to
the mean), subject or investigator expectations, effect of
being in a trial, use of other therapies and subjective ele-
ments of the diagnosis or assessment. The outcome dif-
ferences between the pharmacologically active treatment
and placebo groups define the treatment effect under
trial conditions [5,6].
Allergic diseases are characterised by variable clinical
responses because of the unpredictability and variability
of allergen exposure and, more importantly, the subject-
ive nature of symptom assessment [7]. Accordingly,
double-blind, placebo-controlled trials (DBPC) are rec-
ommended by international guidelines for studies inves-
tigating the efficacy and safety of allergen-specific
immunotherapy (SIT) [8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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controlled studies and refers to the improvement ob-
served in a percentage of patients treated with placebos
in a wide range of clinical conditions, either in trials or
in clinical practice [9]. It is a genuine psychobiological
event attributable to the overall therapeutic context [3].
Psychologically, it is attributed to classical conditioning
mechanisms and patient expectations [3,6,10]. Several
studies have examined the placebo effect in DBPC studies
in trials comparing the placebo with no treatment in dif-
ferent diseases and for different types of outcomes [10-14].
The impact of placebo effects has been described in many
reviews [6]. High rates of placebo efficacy were attained in
a study with patients with atopic dermatitis [10]. Cur-
rently, the placebo effect is discussed in matters of clinical
relevance [15]. Because placebos can actually produce re-
sults comparable to specific drugs without deception
[10,16], it is important to exploit the placebo effect by ap-
plying its mechanisms [17] and thus deliberately boosting
the efficacy of treatments.
The placebo effect has been analysed in different
pharmacologic and placebo treatments in allergic diseases
[7,10,18] but never in placebo-controlled SIT clinical trials.
In SIT trials, treatment efficacy is usually expressed as
the difference between the symptom-medication-score
(SMS) in the active treatment group and the placebo
group after treatment. A proper evaluation of the placebo
effect in SIT trials requires a baseline period to document
the effect of exposure and serves as a reference value for
calculating changes. SIT trials with a baseline season are
limited because they are deemed to be costly and time-
consuming [8].
The aim of this study was to examine the placebo ef-
fect in different SIT trials with comparable designs con-
sisting of one observational season (baseline) followed
by two treatment years using SMS as the efficacy param-
eter. Our data highlight the characteristics and clinical
relevance of the placebo response and provide relevant
information for designing and interpreting future clinical
studies in allergen-specific immunotherapy.
Methods
Study characteristics
To avoid the well-known heterogeneity of SIT studies
and to include in our analysis only comparable trials, we
considered in the present analysis all DBPC phase III
SIT studies of the company (Allergopharma) that were
comparable and homogeneous for all of the following
parameters (n = 6): a prospective baseline observation
period (a baseline season in the case of pollen studies);
the same inclusion and exclusion criteria, as previously
recommended [19]; the same baseline patient clinical
characteristics (adult patients with allergic rhinitis (AR)
with or without bronchial asthma, GINA I and II) [20]; atwo-year treatment period; the same evaluation method
for allergen exposure; the same length of treatment ob-
servation period; a validated method to assess the SMS
[21]; the same method for immunological measure-
ments; and the same components and appearance of pla-
cebo treatments.
Two studies included patients suffering from a grass
pollen allergy, two included patients with a birch pollen al-
lergy and two included patients with a house dust mite
(HDM) allergy (Table 1). Five studies were performed with
subcutaneous immunotherapy (SCIT), and one used a
sublingual extract (SLIT). Three of these studies have been
published before [22-25]; data for the remaining three
(SCIT HDM 2, SCIT Grasses and SCIT Birch 2) have not
yet been published.
For all of the studies ethical and regulatory approval
was obtained from the local ethics committee(s) and the
local health authorities in the respective countries (United
Kingdom, Poland, Germany, Italy, Macedonia, Sweden, and
Finland). Written informed consent was obtained from the
patient for each of the studies prior to any study related
procedure.
The placebo treatment contained all of the constituents
of the active product, except for the allergens. In case of
SCIT, the placebo contained aluminium-hydroxide, and in
three studies, it contained histamine (0.125 mg/ml in the
highest strength) for blinding.
Assessment
The results were reported as changes from the baseline
of the area under the curve (AUC) of SMS after 2 years
of perennial placebo therapy (mean values). The SMS
of all of the included studies was based on the vali-
dated Allergy Control Score™ [21]. The evaluation pe-
riods covered 21 days for birch pollen, 42 days for
grass pollen and 28 days for HDM allergies. To com-
pare the subjective and objective outcomes in the pla-
cebo group, IgG4 changes in the placebo group were
also evaluated.
Assessment of allergen exposure
Because different pollen exposure levels in different sea-
sons can influence the results, the daily mean AUCs of
birch and grass pollen (grains/m3) were assessed during
the evaluation periods (https://ean.polleninfo.eu/Ean/).
Placebo patients were paired with an allocated pollen
trap. The maximum distance between trial centres and
pollen stations was 100 km. If one trap provided no re-
sults, the closest station with results was chosen for the
assessment. Pollen levels were analysed using the median
AUC of the pollen count during the assessment period.
This period began 10 or 7 days before the pollen peak
day and ended 31 days or 13 days after the peak day for
grass or birch pollen, respectively.
Table 1 Characteristics of the evaluated studies and included patients (FAS)
Extract Histamine No. of placebo patients Age (year, mean, ±SD) Gender (M/F)
SCIT HDM 1 (22) + 62 28.6 (±9.8) 36/26
SCIT HDM 2 * + 50 32.0 (±10.2) 25/25
SCIT Grasses * + 87 31.7 (±9.4) 52/35
SLIT Grasses (23,25) - 55 34.1 (±10.3) 32/23
SCIT Birch 1 (24) - 98 38.4 (±11.4) 45/53
SCIT Birch 2 * - 120 39.0 (±11.2) 58/62
Legend: *data on file.
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HDM exposure with a semi-quantitative biochemical
test (Acarex®, Davimed Pharma +HealthCare GmbH,
Germany ) was performed before and 2 years after ther-
apy to ensure comparable exposure during the baseline
and evaluation periods after 2 treatment years.
IgG4 evaluation
In all studies, IgG4 measurements were performed by
the same laboratory using the method described previ-
ously [26].
Results
The six studies included 472 placebo-treated patients
(248 males and 224 females; mean age 34 ± 10.4 years)
(Table 1). A total of 87 patients were treated with SCIT
grass pollen placebo, 55 patients were treated with SLIT
grass pollen placebo, 218 patients were treated with
SCIT birch pollen placebo and 112 patients were treated
with SCIT HDM placebo.
A marked SMS decrease in placebo-treated patients was
detectable in all but the SLIT trial. Table 2 shows the base-
line values for AUC of SMS in these trials and the changes
from baseline after the first and second treatment year.
Figure 1 displays the mean% change from baseline for the
AUC of SMS in the different studies and treatment years,
whereas Figure 2 shows the mean AUC SMS values in the
different studies at baseline and during the evaluation pe-
riods at one and two treatment years. Patients allergic to
pollen showed higher mean daily SMS values at baselineTable 2 Changes from baseline as well as changes in the per
the studies
Extract SMS at baseline SMS mean change from baseline
(mean) 1st yr
SCIT HDM 1 181.7 −44.2
SCIT HDM 2 251.7 −83.7
SCIT grasses 599.3 −98.8
SLIT grasses 484.0 −6.2
SCIT Birch 1 396.9 −205.5
SCIT Birch 2 286.8 −16.8
Legend: *calculated as change/baseline (in%).(14.3/11.5 in the grass trials and 18.9/13.7 in the birch tri-
als) compared to the patients allergic to HDMs (6.5/9).
These data must be matched for the different allergen
exposures faced by placebo patients in the different
studies and evaluation periods. Table 2 shows the pla-
cebo effect in the HDM allergic patients who had a com-
parable HDM allergen exposure at baseline and at the
first and second treatment years. Figure 3 displays the
daily mean pollen exposure at baseline and during the
pollen seasons after one and two treatment years for
grass or birch pollen studies. Grass pollen exposure was
similar throughout the study periods in the SLIT trial
and resulted in −1.3% and +0.7% mean changes in AUC
SMS (Figure 3A). In the SCIT trial, the grass pollen expos-
ure was much higher during the first season and resulted in
a placebo effect of 16.5%; pollen exposure decreased in the
second pollen season but was still enhanced compared to
baseline resulting in a placebo effect of −24.7% (Figure 3B).
The pollen exposure in Birch trial 1 showed even higher
fluctuations, with reduced exposure in the first treatment
year that resulted in a placebo effect of 51.8%, which was
followed by an increase in exposure in the second year
compared to baseline (a 24.5% placebo effect) (Figure 3C).
Birch pollen exposure was constant in Birch Trial 2. The
placebo effect was only 5.9% in the first treatment year and
increased to 18.3% in the second year (Figure 3D).
For five of the six trials, IgG4 values, which were eval-
uated using a comparable method, were available. Con-
trary to the clinical data, the IgG4 levels did not change
in placebo patients during the two years of treatment.cent of the AUC of SMS in the placebo group during
SMS mean change from baseline Placebo effect SMS %*







Figure 1 Mean% change from baseline for the AUC of SMS in the different studies and treatment years.
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The present investigation is the first analysis of the pla-
cebo response in adult allergic patients enrolled in SIT
trials with homogeneous study designs, comparing this
response in different allergens and different routes of ad-
ministration. All of the studies covered a two-year treat-
ment period after a baseline observation phase and used
a similar tool to assess efficacy after treatment. Our data
showed a high placebo effect in SIT, which was much
less prominent in SLIT than in SCIT.
The nervous system and psychological effects are im-
portant features of allergic and immunological reactions
[7], both in asthma and AR [27,28]. Allergic diseases
constitute a group that is highly susceptible to placebo
effects, and this effect has been evaluated in placebo-
controlled studies of anti-allergic drugs [18].Figure 2 Mean AUC of SMS at baseline after the first and the second
Legend: the SDs are as follows: SCIT HDM 1 (baseline ±104, first year ±112,
year ±104), SCIT grasses (baseline ±295, first year ±294, second year ±305),
birch 1 (baseline ±156, first year ±133, second year ±168), SCIT birch 2 (basA meta-analysis of the efficacy of different drug treat-
ments authorised in the United States for allergic rhinitis
showed a 15% improvement in the total symptom score
(TSS) for seasonal AR and a 24.8% improvement for per-
ennial AR in placebo-treated patients [29]. Similar placebo
effects have been detected in a meta-analysis evaluating
the efficacy of antihistamines, inhaled steroids and a long-
acting β-agonist in AR, allergic asthma and atopic derma-
titis; the analysis observed an average placebo effect of
23.0% [7]. A subsequent study investigating the efficacy of
different antihistamines compared to placebos in patients
with AR found no significant difference between the treat-
ment groups. The physicians’ assessments showed 44%
and 40% overall treatment success rates for the antihista-
mines fexofenadine HCl and loratadine, respectively, and a
36% treatment success rate in the placebo group. Thetreatment year in the placebo groups of the different trials.
second year ±109), SCIT HDM 2 (baseline ±122, first year ±110, second
SLIT grasses (baseline ±218, first year ±321, second year ±300), SCIT
eline ±131, first year ±162, second year ±168).
Figure 3 Daily mean pollen count during baseline and the first and second treatment years in the different pollen trials. Legend: A SLIT
grasses, B SCIT grasses, C birch trial 1, D birch trial 2.
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47%, 42% and 37%, for fexofenadine HCl, loratadine and a
placebo, respectively [30].
It is well known that subjective endpoints (e.g., patient-
reported outcomes and observer-reported outcomes in-
volving patient cooperation) are more susceptible to
placebo effects than objective variables [9,13,31]. This
finding was also confirmed by our analysis; despite the
marked placebo effect in SMS, no change from baseline in
allergen specific IgG4 antibodies was observed in the pla-
cebo groups.
It has also been reported that the exposure route plays
an important role in the magnitude of the placebo effect
and that injections cause greater placebo effects than
tablets or oral applications [32,33]. An increased placebo
response was observed in the five studies using subcuta-
neous therapy compared with the SLIT study (max.
40.5% for SCIT versus 1.3% for SLIT in studies with
comparable allergen exposure), which confirms that the
administration route may result in different magnitudes
of placebo effect in SIT trials. Although we could only
include one SLIT trial, other trials support our results,both in studies with comparable pollen counts and in
those with comparable mite exposures [34-36]. Ott et al.
(35) showed no effect or a worsening in the SLIT pla-
cebo group during 3 years of treatment, and a placebo
effect could only be observed in the follow-up period
due to lower pollen exposure. The very low placebo effect
in the SLIT studies is in contrast to the average placebo ef-
fect of 23% for pharmacotherapy of allergic diseases, as
shown in a US meta-analysis [7]. One reason for this may
be the long duration of SIT trials in contrast to studies
with pharmacotherapy where patients will realise the bur-
den of their disease over time. The contribution of the
lower SMS in the SLIT versus the SCIT grass trial to the
low placebo effect in the SLIT trial seems to be unlikely
because even in the other SCIT trials with lower SMS
values at baseline, a high placebo effect could be observed.
Previous SCIT publications have also reported placebo ef-
fects similar to our study. Blumberga et al. [37] found 25%
and 42% decreases in inhaled steroid use in placebo pa-
tients after 2 and 3 years, respectively. Varney et al. [38]
observed a 32% reduction in symptom scores after 1 year
of placebo SCIT treatment for patients with mite allergies.
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scores and 18% in medication scores in placebo-treated-
patients with grass allergies, although the pollen exposure
was higher in the observation period after the treatment
[39]. We could not include these SLIT and SCIT studies in
our analysis due to the high heterogeneity of study designs
and methods. Furthermore, we excluded studies in chil-
dren or using pollen chambers because this would have
added further complexity.
In addition to the administration route, one reason for
the high placebo effects in SCIT may be that, according
to clinical guidelines, the placebo must have the exact
same composition as the active treatment, except for the
allergen. The placebo in the analysed SCIT trials con-
tained aluminium hydroxide and occasionally histamine
for blinding. The known adjuvant effect of aluminium
hydroxide may have contributed to the placebo effect in
SCIT. Furthermore, the high placebo effect in the SCIT
trials was a good indication that the blinding was effect-
ive in these clinical trials.
A highly important but simple reason for the high pla-
cebo effect in SCIT may be the fact that patients are
taken care of regularly; they have to come to their phys-
ician to receive the injections; the patients and physi-
cians have regular discussions about the disease and
treatment, and exacerbations and other issues can be
handled immediately. Consequently, patients will gener-
ally consider the burden of their disease less severe. The
SLIT treatment is home-based, and the patients are left
on their own without health care support and again will
most likely have a minor placebo effect. However in a
study setting, contact with physicians is normally still
higher than in daily practice.
The DBPC studies analysed here reported in a prospect-
ive manner a baseline period monitored with the same
outcomes, methods and scores used for post-treatment
evaluation. Unfortunately, the majority of SIT studies do
not include a baseline observation. Therefore, they can
only assess a final difference between active- and placebo-
treated patients but not real improvements or the placebo
response. Some pollen trials assess baseline values retro-
spectively, but this method is not suitable because of many
biases, the most important being a memory bias [40]. Offi-
cial documents now recommend the inclusion of a pro-
spective baseline period [41], although the World Allergy
Organization states that although the inclusion of a base-
line observation is correct in principle, it is not mandatory
because it is “expensive and time consuming” [8].
Placebo patients who are allergic to pollen showed
higher SMS values compared to patients that are allergic
to HDM, most likely because of a reduced awareness of
symptoms in perennial exposure. However, even this re-
duced “room for improvement” resulted in a high pla-
cebo effect that was up to 40.5%.To evaluate placebo effects, the amount of exposure is
critical. Our analysis showed that in HDM-allergic patients
with comparable exposures between the baseline and the
end of the treatment period, the placebo effect in SCIT
ranged from 24.3% to 29.7% in study 1 and from 33.2% to
40.5% in study 2. With increased exposure, a reduced pla-
cebo effect resembling the SCIT grass trial (16.5% and
24.7%) or the second pollen season in Birch trial 1 (24.5%)
was observed. In contrast, a low pollen exposure resulted in
a high placebo effect of up to 51.8% (first year of Birch trial
1). The only exception seemed to be the low placebo effect
in the first year of Birch trial 2, although no clear reason
was apparent. We have analysed the relationship between
changes in the SMS and pollen count and found statistically
significant correlations for all studies and all treatment
years. Thus, it can be concluded that the amount of aller-
gen exposure is causally related to the magnitude of the
placebo effect.
The high placebo effect observed in this SIT analysis
must not be ignored and obviously needs further research
on the placebo effectiveness in the clinical context of im-
munotherapy targeting the underlying mechanisms of this
genuine psychobiological event. Classical conditioning as
well as expectations induced via instructions enable the
release of endogenous neurotransmitters, which imitate
the expected or conditioned pharmacological effects in the
sense of placebo effects [3,42,43]. In a sample of patients
with atopic dermatitis, we previously showed that an anal-
gesic placebo effect was also established via expectations
induced by both mechanisms, i.e., classical conditioning
and instructions; however, compared to the healthy con-
trol group in the patient group, the effect was maintained
only in the groups who experienced classical conditioning
[10]. This means that the experience of symptom relief is
necessary to learn the placebo effect. Benedetti and col-
leagues [44] showed that analgesics always consist of two
components, a pharmacological and a psychological (pla-
cebo) component. They proved this assumption within an
alternative model of the double-blind, randomised con-
trolled trials, namely, the “open-hidden paradigm”. Here,
identical concentrations of active drugs are administered
by a physician in an appreciable, e.g., visible (open condi-
tion) or hidden, manner (drug given by a computer), in
which the patient is unaware of the timing of medication
administration. So it is possible to dissociate the pure
pharmacological effect of the treatment (hidden treat-
ment) from the additional benefit of the psychological
context resulting from knowing that the treatment is being
administered. The difference between the outcomes fol-
lowing the administration of the expected and unexpected
therapy can be seen as the placebo response or psycho-
logical component, even though no placebo treatment has
been used. These findings require exploitation of the pla-
cebo effect in pharmacological treatment as much as
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add-on to the pharmacological component of a medication.
Conclusions
In conclusion, we detected a placebo effect in SCIT trials
from 24% to 41% in mite and from 6% to 25% in pollen al-
lergic patients with comparable allergen exposure and up
to 51.8% with reduced exposure, which is in contrast to
1.3% or less in the SLIT trial. The differences between the
SCIT and SLIT trials may be explained by the treatment
method (i.e., injections versus oral applications) or the
ingredients, such as aluminium hydroxide or histamine,
included in the placebos in the SCIT trials in order to
meet regulatory requirements or to maintain blinding.
This observation underscores the value of a proper base-
line observation period in SIT placebo-controlled trials.
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